AKT1 and neoplasm: PD biomarkers of target engagement (pAKT/AKT ratio) and STX-478 plasma and tumor drug levels were measured 1, 4, and 12 hours after dose on day 3 (PK/PD group), and 1 and 6 hours after final dose (day 28).